Literature DB >> 16707475

Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.

Laurence Chapatte1, Maha Ayyoub, Sandra Morel, Anne-Lise Peitrequin, Nicole Lévy, Catherine Servis, Benoît J Van den Eynde, Danila Valmori, Frédéric Lévy.   

Abstract

Dendritic cells are unique in their capacity to process antigens and prime naive CD8(+) T cells. Contrary to most cells, which express the standard proteasomes, dendritic cells express immunoproteasomes constitutively. The melanoma-associated protein Melan-A(MART1) contains an HLA-A2-restricted peptide that is poorly processed by melanoma cells expressing immunoproteasomes in vitro. Here, we show that the expression of Melan-A in dendritic cells fails to elicit T-cell responses in vitro and in vivo because it is not processed by the proteasomes of dendritic cells. In contrast, dendritic cells lacking immunoproteasomes induce strong anti-Melan-A T-cell responses in vitro and in vivo. These results suggest that the inefficient processing of self-antigens, such as Melan-A, by the immunoproteasomes of professional antigen-presenting cells prevents the induction of antitumor T-cell responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707475     DOI: 10.1158/0008-5472.CAN-05-4310

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.

Authors:  Benoît Guillaume; Jacques Chapiro; Vincent Stroobant; Didier Colau; Benoît Van Holle; Grégory Parvizi; Marie-Pierre Bousquet-Dubouch; Ivan Théate; Nicolas Parmentier; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

2.  Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.

Authors:  Ozcan Met; Jens Eriksen; Inge Marie Svane
Journal:  Mol Biotechnol       Date:  2008-06-10       Impact factor: 2.695

Review 3.  Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.

Authors:  Yukai He; David Munn; Louis D Falo
Journal:  Expert Rev Vaccines       Date:  2007-12       Impact factor: 5.217

4.  Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.

Authors:  Lijin Li; John M Herndon; Steven M Truscott; Ted H Hansen; Timothy P Fleming; Peter Goedegebuure; William E Gillanders
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 5.  Basic and translational applications of engineered MHC class I proteins.

Authors:  Ted H Hansen; Janet M Connolly; Keith G Gould; Daved H Fremont
Journal:  Trends Immunol       Date:  2010-09-09       Impact factor: 16.687

Review 6.  Potential targets for pancreatic cancer immunotherapeutics.

Authors:  Lindzy F Dodson; William G Hawkins; Peter Goedegebuure
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

Review 7.  Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.

Authors:  Nathalie Vigneron; Benoît J Van den Eynde
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

8.  Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.

Authors:  Marlène Brandes; Katharina Willimann; Gilles Bioley; Nicole Lévy; Matthias Eberl; Ming Luo; Robert Tampé; Frédéric Lévy; Pedro Romero; Bernhard Moser
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

9.  Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway.

Authors:  Faten El Hage; Vincent Stroobant; Isabelle Vergnon; Jean-François Baurain; Hamid Echchakir; Vladimir Lazar; Salem Chouaib; Pierre G Coulie; Fathia Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-14       Impact factor: 11.205

10.  Immunoproteasomes edit tumors, which then escapes immune recognition.

Authors:  Sebastian Joyce
Journal:  Eur J Immunol       Date:  2015-11-17       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.